Hayden Royal’s Altimmune ALT Stock Holding History

Hayden Royal’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-44,583	Closed	-$630K	–	208
2021 Q1	$630K	Buy	44,583 +200	+0.5%	+$3.23K	0.36%	67
2020 Q4	$501K	Buy	44,383 +12,000	+37%	+$141K	0.27%	84
2020 Q3	$427K	Buy	32,383 +22,283	+221%	+$445K	0.23%	106
2020 Q2	$108K	Buy	+10,100	New	+$55.5K	0.06%	158

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hayden Royal's ALT Position: Q2 2021 in Review

Hayden Royal sold out of Altimmune (ALT) in Q2 2021, closing a stake of 44,583 shares — an estimated $630K sold.

Hayden Royal first reported a position in ALT in Q2 2020 and held it in 4 quarters. The position peaked at $630K in Q1 2021. 109 funds tracked by Wall St. Rank hold ALT as of Q2 2021.

Hayden Royal reported no remaining Altimmune position as of Q2 2021 after selling out during the quarter.
Hayden Royal sold 44,583 Altimmune shares in Q2 2021, an estimated $630K.
Hayden Royal first reported a position in Altimmune in Q2 2020 and held it in 4 quarters.
Hayden Royal's Altimmune position peaked at $630K in Q1 2021.
109 funds tracked by Wall St. Rank held Altimmune as of Q2 2021.

Based on Hayden Royal's 13F filing for Q2 2021, filed 11 Aug 2021.